Company Overview: Claritev Corporation, formerly MultiPlan, is a healthcare technology and data insights company focused on improving affordability, transparency, and quality in the healthcare system.
Management Participation: Members of Claritev's management team will participate in various conferences in September 2025, with live webcasts and audio archives available on their investor relations website.
Innovative Solutions: The company leverages advanced technology, AI solutions, and over 40 years of claims repricing experience to provide meaningful insights and support for payors, employers, patients, providers, and third parties.
Mission Statement: Claritev aims to make healthcare more accessible and affordable by delivering purpose-built solutions that enhance the overall healthcare experience for all stakeholders involved.
CTEV
$38.35+Infinity%1D
Analyst Views on CTEV
Wall Street analysts forecast CTEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTEV is 85.00 USD with a low forecast of 80.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CTEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTEV is 85.00 USD with a low forecast of 80.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 37.960
Low
80.00
Averages
85.00
High
90.00
Current: 37.960
Low
80.00
Averages
85.00
High
90.00
Piper Sandler
Overweight
maintain
$86 -> $90
2025-11-10
Reason
Piper Sandler
Price Target
$86 -> $90
2025-11-10
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Claritev to $90 from $86 and keeps an Overweight rating on the shares. The firm notes Q3 revenue of $246.0M beat consensus at $235.8M and was up 6.7% year-over-year behind continued strength in analytics-based and network-based revenue.
Citi
Buy
upgrade
$74 -> $80
2025-11-10
Reason
Citi
Price Target
$74 -> $80
2025-11-10
upgrade
Buy
Reason
Citi raised the firm's price target on Claritev to $80 from $74 and keeps a Buy rating on the shares.
Citi
Neutral -> Buy
upgrade
$55 -> $74
2025-10-22
Reason
Citi
Price Target
$55 -> $74
2025-10-22
upgrade
Neutral -> Buy
Reason
Citi yesterday morning upgraded Claritev to Buy from Neutral with a price target of $74, up from $55. The firm has confidence in the company's plan to accelerate growth. It believes Claritev will get back to mid-single-digit growth in 2026 while keeping "best-in-class" margins, the analyst told investors in a research note. This report corrects the price target on the shares.
Citi
Neutral -> Buy
upgrade
$55
2025-10-21
Reason
Citi
Price Target
$55
2025-10-21
upgrade
Neutral -> Buy
Reason
Citi upgraded Claritev to Buy from Neutral with an unchanged price target of $55 ahead of the Q3 report. The firm has confidence in the company's plan to accelerate growth. It believes Claritev will get back to mid-single-digit growth in 2026 while keeping "best-in-class" margins, the analyst tells investors in a research note.
About CTEV
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
